A CLINICAL CASE OF BULEVIRTIDE THERAPY FOR CHRONIC HDV-INFECTION
Abstract
Background. The Republic of Sakha (Yakutia) is an endemic region for chronic hepatitis D, where the detection rate of antibodies to the delta virus is 35% [3]. The urgency of the problem of HDV infection is also determined by its aggressive and rapidly progressive course. In 2019, Bulevirtide, a drug for the treatment of chronic delta hepatitis, was registered in Russia. Three randomized trials showed a high rate of virological, biochemical response, as well as good tolerability and safety. Objective – to evaluate the efficacy and safety of Bulevirtide in the treatment of chronic HDV infection. Material and methods. A clinical case of a patient L. suffering from a chronic form of HDV infection receiving antiviral therapy is presented. Results. Bulevirtide demonstrated high efficacy, as evidenced by the development of a virological response during the first 14 weeks of therapy and a decrease in HDV RNA to an undetectable level within 29. Conclusions. It is necessary to widely introduce Bulevirtide for the treatment of patients with chronic delta hepatitis due to its high efficacy and safety.
References
Yushchuk ND, Vengerov YuYa, editors. Infekcionnye bolezni. 2nd ed. Moskva: GEOTAR-Media; 2018. 1104 p.(Russian).
Ilchenko LJu, Isaeva OV, Malinnikova EJu, Mihajlov MI, Novak KE, Jesaulenko EV, Chulanov VP, Bogomolov PO. Hronicheskij virusnyj gepatit D (HVGD) u vzroslyh. Klinicheskie rekomendacii. Moskva; 2021. 42 p. (Russian).
Sleptsova SS. Parenteralnye virusnye gepatity i ih ishody v Respublike Saha (Jakutija). Moskva: Chehovskij Pechatnyj Dvor; 2017. 216 p. edn: ZHUOKX (Russian).
Bogomolov PO, Ivashkin VT, Bueverov AO, Syutkin VE, Sagalova OI, Sleptsova SS, Yushchuk ND, Gusev DA, Zhdanov KV, Chulanov VP. Jeffektivnost i bezopasnost bulevirtida v lechenii hronicheskogo gepatita D - rezultaty randomizirovannyh kontroliruemyh issledovanij [Efficacy and safety of bulevirtide in the treatment of chronic hepatitis D - results of randomized controlled trials]. Infekcionnye bolezni [Infectious diseases]. 2020;18(4):153 162. https://doi.org/10.20953/1729-9225-2020-4-153-162. https://elibrary.ru/itcbjt. (Russian).
Registr bolnyh virusnymi gepatitami. Sistema monitoringa bolnyh virusnymi gepatitami [Internet]. Available from:https://hepreg.ru/start.html.
Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut. 2021;70(9):1782-1794. https://doi.org/10.1136/gutjnl-2020-323888.
Collier MG, Schillie S. 213 - Hepatitis B and Hepatitis D Viruses. In: Long SS, Prober CG, Fischer M, editors. Principles and Practice of Pediatric Infectious Diseases. 5th ed. Cham: Elsevier; 2018. p. 1107-1114. https://doi.org/10.1016/B978-0-323-40181-4.00213-9.
